Form 4: Vertex Pharmaceuticals Director Bruce Sachs Acquires Deferred Stock Units

Director Bruce Sachs acquired deferred stock units representing common stock in Vertex Pharmaceuticals.

Summary

• On April 15, 2024, Bruce I Sachs, a director of Vertex Pharmaceuticals, acquired deferred stock units representing 109.49 shares of common stock at a price of $399.58 per unit.
• Following the transaction, Mr. Sachs beneficially owns 14,853.748 shares of Vertex Pharmaceuticals common stock.
• The deferred stock units are payable in common stock upon the earliest of Mr. Sachs' termination of service on the board, a change of control of the company, or Mr. Sachs' disability or death.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a transaction. It doesn't contain information that would significantly sway sentiment positively or negatively.

Industry Context

This filing is a routine disclosure of a director's acquisition of deferred stock units, a common form of equity compensation in publicly traded companies.

Stakeholder Impact

• The acquisition of deferred stock units by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates